Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 4/20 | 0.44 |
| ▸ | EPHB3 | P54753 | 5/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA3 | P07451 | 1/20 | 0.41 |
| ▸ | CA6 | P23280 | 1/20 | 0.41 |
| ▸ | CA5A | P35218 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.41 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | KLF5 | Q13887 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12689690 | 0.90 | SMN1; SMN2 (0.47) | IRAK4EPHB3LMNAKDM4ESMN1; SMN2 | |
| SCHEMBL2175323 | 0.88 | LOXL2 (0.44) | EPHB3LMNAKDM4ESMN1; SMN2ALDH1A1 | |
| SCHEMBL16882487 | 0.88 | DRD2 (0.42) | IRAK4EPHB3LMNAKDM4ESMN1; SMN2 | |
| SCHEMBL22228625 | 0.86 | SMN1; SMN2 (0.45) | LMNACA12CA2CA3CA6 | |
| SCHEMBL25366689 | 0.82 | IRAK4 (0.42) | IRAK4EPHB3LMNACA12CA2 | |
| SCHEMBL13452789 | 0.81 | EPHB3 (0.38) | IRAK4EPHB3LMNAKDM4ESMN1; SMN2 | |
| SCHEMBL17320982 | 0.81 | EPHB3 (0.56) | IRAK4EPHB3LMNAKDM4ESMN1; SMN2 | |
| SCHEMBL19786566 | 0.81 | EPHB3 (0.44) | IRAK4EPHB3LMNACA12CA2 | |
| SCHEMBL3612196 | 0.81 | CA12 (0.46) | IRAK4EPHB3LMNACA12CA2 | |
| SCHEMBL2177261 | 0.80 | DRD2 (0.38) | EPHB3LMNAKDM4ESMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260049080-A1 | WILD TYPE KIT INHIBITORS | BLUEPRINT MEDICINES CORP (US) | 2026-02-19 | — | — | US | disclosed |
| US-12448379-B2 | Wild type kit inhibitors | BLUEPRINT MEDICINES CORPORATION (US) | 2025-10-21 | — | — | US | disclosed |
| US-20250099462-A1 | Certain Triazolopyridines and Triazolopyrazines, Compositions Thereof and Methods of Use Therefor | HUTCHISON MEDIPHARMA LTD (CN) | 2025-03-27 | — | — | US | disclosed |
| US-20240262826-A1 | WILD TYPE KIT INHIBITORS | BLUEPRINT MEDICINES CORPORATION | 2024-08-08 | — | — | US | disclosed |
| WO-2024118887-A1 | N-PHENYL-PYRAZOLO[1,5-A]PYRIDINE-3-CARBOXAMIDE DERIVATIVES AS WILD TYPE C-KIT KINASE INHIBITORS FOR THE TREATMENT OF URTICARIA | BLUEPRINT MEDICINES CORPORATION (US) | 2024-06-06 | — | — | WO | disclosed |
| US-20240139182-A1 | Certain Triazolopyridines and Triazolopyrazines, Compositions Thereof and Methods of Use Therefor | HUTCHISON MEDIPHARMA LTD (CN) | 2024-05-02 | — | — | US | disclosed |
| US-11896592-B2 | Certain triazolopyridines and triazolopyrazines, compositions thereof and methods of use therefor | HUTCHISON MEDIPHARMA LIMITED (CN) | 2024-02-13 | — | — | US | disclosed |
| EP-3795573-B1 | CERTAIN TRIAZOLOPYRAZINES, COMPOSITIONS THEREOF AND METHODS OF USE THEREFOR | HUTCHISON MEDIPHARMA LTD (CN) | 2022-07-06 | — | — | EP | disclosed |
| EP-3795573-B1 | CERTAIN TRIAZOLOPYRAZINES, COMPOSITIONS THEREOF AND METHODS OF USE THEREFOR | HUTCHISON MEDIPHARMA LTD (CN) | 2022-07-06 | — | — | EP | disclosed |
| US-20210154192-A1 | CERTAIN TRIAZOLOPYRIDINES AND TRIAZOLOPYRAZINES, COMPOSITIONS THEREOF AND METHODS OF USE THEREFOR | HUTCHISON MEDIPHARMA LIMITED (CN) | 2021-05-27 | — | — | US | disclosed |
| WO-2011079804-A1 | CERTAIN TRIAZOLOPYRIDINES AND TRIAZOLOPYRAZINES, COMPOSITIONS THEREOF AND METHODS OF USE THEREFOR | HUTCHISON MEDIPHARMA LIMITED (CN) | 2011-07-07 | — | — | WO | disclosed |
| WO-2011079804-A1 | CERTAIN TRIAZOLOPYRIDINES AND TRIAZOLOPYRAZINES, COMPOSITIONS THEREOF AND METHODS OF USE THEREFOR | HUTCHISON MEDIPHARMA LIMITED (CN) | 2011-07-07 | — | — | WO | disclosed |
| US-20100168125-A1 | INDOLIZINES AND AZA-ANALOG DERIVATIVES THEREOF AS CNS ACTIVE COMPOUNDS | DONSBACH, MARTIN (DE) | 2010-07-01 | — | — | US | disclosed |
| EP-2137185-A2 | INDOLIZINES AND AZA-ANALOG DERIVATIVES THEREOF AS CNS ACTIVE COMPOUNDS | Gmeiner, Dr. Peter (DE) | 2009-12-30 | — | — | EP | disclosed |
| US-20080262027-A1 | Novel Chemical Compounds | DUFFY KEVIN J | 2008-10-23 | — | — | US | disclosed |
| WO-2008113559-A2 | INDOLIZINES AND AZA-ANALOG DERIVATIVES THEREOF AS CNS ACTIVE COMPOUNDS | SCHWARZ PHARMA AG (DE) | 2008-09-25 | — | — | WO | disclosed |
| EP-1972628-A1 | Indolizines and aza-analog derivatives thereof as CNS active compounds | SCHWARZ PHARMA AG (DE) | 2008-09-24 | — | — | EP | disclosed |
| EP-1954136-A2 | NOVEL CHEMICAL COMPOUNDS | SmithKline Beecham Corporation (US) | 2008-08-13 | — | — | EP | disclosed |
| US-20080051409-A1 | Indolizine Carboxamides and Aza and Diaza Derivatives Thereof | SCHWARZ PHARMA AG (DE) | 2008-02-28 | — | — | US | disclosed |
| WO-2007056683-A2 | NOVEL CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168125-A1 | INDOLIZINES AND AZA-ANALOG DERIVATIVES THEREOF AS CNS ACTIVE COMPOUNDS | INMT, AANAT, AZI2 | IRAK4 3869/4885EPHB3 2529/4885LMNA 4009/4885 |
| US-20080262027-A1 | Novel Chemical Compounds | HIPK3, DAPK3, YARS1 | IRAK4 1802/4885EPHB3 3374/4885LMNA 2777/4885 |
| US-20260049080-A1 | WILD TYPE KIT INHIBITORS | KIT, CSNK1A1, CSNK1A1L | IRAK4 265/4885EPHB3 2198/4885LMNA 2701/4885 |
| US-20080051409-A1 | Indolizine Carboxamides and Aza and Diaza Derivatives Thereof | GRIN2A, GRIN2C, GRIN1 | IRAK4 802/4885EPHB3 2569/4885LMNA 4242/4885 |
| US-20210154192-A1 | CERTAIN TRIAZOLOPYRIDINES AND TRIAZOLOPYRAZINES, COMPOSITIONS THEREOF AND METHODS OF USE THEREFOR | KCNJ11, NISCH, CYP4Z1 | IRAK4 2782/4885EPHB3 2397/4885LMNA 3230/4885 |
| US-12448379-B2 | Wild type kit inhibitors | KIT, TNK1, TNNI3K | IRAK4 335/4885EPHB3 2426/4885LMNA 2637/4885 |
| US-11896592-B2 | Certain triazolopyridines and triazolopyrazines, compositions thereof and methods of use therefor | TK2, TYMP, DPYD | IRAK4 2575/4885EPHB3 3488/4885LMNA 1921/4885 |
| US-20240262826-A1 | WILD TYPE KIT INHIBITORS | KIT, TNK1, TNNI3K | IRAK4 335/4885EPHB3 2426/4885LMNA 2637/4885 |
| US-20250099462-A1 | Certain Triazolopyridines and Triazolopyrazines, Compositions Thereof and Methods of Use Therefor | KCNJ11, NISCH, CYP4Z1 | IRAK4 2782/4885EPHB3 2397/4885LMNA 3230/4885 |
| US-20240139182-A1 | Certain Triazolopyridines and Triazolopyrazines, Compositions Thereof and Methods of Use Therefor | KCNJ11, NISCH, CYP4Z1 | IRAK4 2782/4885EPHB3 2397/4885LMNA 3230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.